Advertisement
Advertisement
ALZN
Alzamend Neuro, Inc. Common Stock
1.98
USDSponsored
+0.13
+7.22%
Feb 06, 15:59 UTC -5
Closed
Pre-Market
2.04
+0.06
+3.28%
ALZN Earnings Reports
Positive Surprise Ratio
ALZN beat 8 of 16 last estimates.
50%
Next Report
Date of Next Report
Mar 09, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$1.96
Implied change from Q2 26 (Revenue/ EPS)
--
/+553.33%
Implied change from Q3 25 (Revenue/ EPS)
--
/+14.62%
Alzamend Neuro, Inc. Common Stock earnings per share and revenue
On Dec 09, 2025, ALZN reported earnings of -0.30 USD per share (EPS) for Q2 26, beating the estimate of -1.99 USD, resulting in a 84.96% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -0.46% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 4 analysts forecast an EPS of -1.96 USD, with revenue projected to reach -- USD, implying an increase of 553.33% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AYTU BioPharma, Inc. Common Stock
Report Date
Feb 03, 2026 For Q2 26
Estimate
-$0.61
Actual
-$1.05
Surprise
-71.57%
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
FAQ
What were Alzamend Neuro, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Alzamend Neuro, Inc. Common Stock reported EPS of -$0.30, beating estimates by 84.96%, and revenue of $0.00, 0% as expectations.
How did the market react to Alzamend Neuro, Inc. Common Stock's Q2 2026 earnings?
The stock price moved down -0.46%, changed from $2.17 before the earnings release to $2.16 the day after.
When is Alzamend Neuro, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 09, 2026.
What are the forecasts for Alzamend Neuro, Inc. Common Stock's next earnings report?
Based on 4
analysts, Alzamend Neuro, Inc. Common Stock is expected to report EPS of -$1.96 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement